What defines disease in an age of genetics and biomarkers?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 22, Issue 4, 2015, Pages 296-299

  Gottlieb, Peter A ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

autoantibodies; autoimmunity; autoreactive T cells; innate immunity; prevention; T regulatory cells; type 1 diabetes

Indexed keywords

AUTOANTIBODY; HEMOGLOBIN A1C; HLA DRB1 ANTIGEN; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; BIOLOGICAL MARKER;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CLINICAL EFFECTIVENESS; DISEASE COURSE; DYSGLYCEMIA; ENVIRONMENTAL EXPOSURE; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC RISK; GENETICS; HUMAN; HYPERGLYCEMIA; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; IMPAIRED GLUCOSE TOLERANCE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL; PRIMARY PREVENTION; REGULATORY T LYMPHOCYTE; REHABILITATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; T LYMPHOCYTE; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY;

BIOMARKERS; DIABETES MELLITUS, TYPE 1; HUMANS;

EID: 84937797480     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000172     Document Type: Review

References (17)

1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014; 383: 69-82
2. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013; 309: 2473-2479
3. Steck AK, Vehik K, Bonifacio E, et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: the environmental determinants of diabetes in the young (TEDDY). Diabetes Care. 2015; 38: 808-813
4. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-Analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009; 41: 703-707
5. Onengut-Gumuscu S, Chen WM, Burren O, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015; 47: 381-386
6. Smith MJ, Packard TA, ONeill SK, et al. Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients. Diabetes. 2015; 64: 1703-1712
7. Menard L, Saadoun D, Isnardi I, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Investig. 2011; 121: 3635-3644
8. Alkanani AK, Rewers M, Dong F, et al. Dysregulated Toll-like receptor-induced interleukin-1beta and interleukin-6 responses in subjects at risk for the development of type 1 diabetes. Diabetes. 2012; 61: 2525-2533
9. Ferreira RC, Guo H, Coulson RM, et al A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes. 2014; 63: 2538-2550
10. Chen YG, Cabrera SM, Jia S, et al. Molecular signatures differentiate immune states in type 1 diabetic families. Diabetes. 2014; 63: 3960-3973
11. Sosenko JM, Skyler JS, Palmer JP, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care. 2013; 36: 2615-2620
12. Orban T, Beam CA, Xu P, et al. Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-Treated patients with recentonset type 1 diabetes is associated with slower C-peptide decline. Diabetes. 2014; 63: 3449-3457
13. Rigby MR, DiMeglio LA, Rendell MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013; 1: 284-294
14. Schneider A, Rieck M, Sanda S, et al. The effector T cells of diabetic subjects are resistant to regulation via CD4 FOXP3 regulatory T cells. J Immunol. 2008; 181: 7350-7355
15. Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4()CD25() regulatory T-cells of type 1 diabetic subjects. Diabetes. 2010; 59: 407-415
16. Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes. 2012; 61: 2340-2348
17. Sosenko JM, Skyler JS, Beam CA, et al. Acceleration of the loss of the firstphase insulin response during the progression to type 1 diabetes in diabetes prevention trial-Type 1 participants. Diabetes. 2013; 62: 4179-4183